{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:04:59Z","timestamp":1780085099427,"version":"3.54.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,12]],"date-time":"2015-08-12T00:00:00Z","timestamp":1439337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-1093-7","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T12:04:59Z","timestamp":1439294699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature"],"prefix":"10.1186","volume":"15","author":[{"given":"Richard","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Barrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,12]]},"reference":[{"key":"1093_CR1","first-page":"19","volume":"50","author":"AD Jenssen","year":"1969","unstructured":"Jenssen AD. Chronic calcified pleural empyema. Scand J Respir Dis. 1969;50:19\u201327.","journal-title":"Scand J Respir Dis"},{"key":"1093_CR2","first-page":"82","volume":"14","author":"SA Sahn","year":"1999","unstructured":"Sahn SA, Iseman MD. Tuberculous empyema. Sem Respir Infect. 1999;14:82\u20137.","journal-title":"Sem Respir Infect"},{"key":"1093_CR3","first-page":"247","volume-title":"Pleural Diseases","author":"RW Light","year":"2013","unstructured":"Light RW. Tuberculous Pleural Effusions. In: Light RW, editor. Pleural Diseases. 6th ed. New York, NY: Lippincott Williams & Wilkins; 2013. p. 247\u201362.","edition":"6"},{"key":"1093_CR4","first-page":"616","volume":"71","author":"WH Roper","year":"1955","unstructured":"Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Respir Dis. 1955;71:616\u201334.","journal-title":"Am Rev Respir Dis"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1378\/chest.128.5.3240","volume":"128","author":"DH Han","year":"2005","unstructured":"Han DH, Song JW, Chung HS. Resolution of residual pleural disease according to time course in tuberculous pleurisy during and after the termination of antituberculosis medication. Chest. 2005;128:3240\u20135.","journal-title":"Chest"},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1378\/chest.100.1.124","volume":"100","author":"MD Iseman","year":"1991","unstructured":"Iseman MD, Madsen LA. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance. Chest. 1991;100:124\u20137.","journal-title":"Chest"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0962-8479(95)90016-0","volume":"76","author":"AM Elliot","year":"1995","unstructured":"Elliot AM, Berning SE, Iseman MD, Peloquin CA. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis. 1995;76:463\u20137.","journal-title":"Tubercle Lung Dis"},{"key":"1093_CR8","first-page":"59","volume-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","author":"CA Peloquin","year":"1991","unstructured":"Peloquin CA. Antituberculosis Drugs: Pharmacokinetics. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 59\u201388."},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2174\/092986708783955509","volume":"15","author":"NR Budha","year":"2008","unstructured":"Budha NR, Lee RE, Meibohm B. Biopharmaceutics, pharmacokinetics, and pharmacodynamics of antituberculosis drugs. Curr Medicinal Chem. 2008;15:809\u201325.","journal-title":"Curr Medicinal Chem"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1128\/AAC.01036-07","volume":"52","author":"CA Peloquin","year":"2008","unstructured":"Peloquin CA, Hadad DJ, Molina LPD, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1128\/AAC.01474-09","volume":"54","author":"T Gumbo","year":"2010","unstructured":"Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1481\u201391.","journal-title":"Antimicrob Agents Chemother"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1155\/2008\/747206","volume":"15","author":"R Long","year":"2008","unstructured":"Long R, Barrie J, Stewart K, Peloquin C. Treatment of tuberculous empyema with simultaneous oral and intrapleural antituberculosis drugs. Can Respir J. 2008;15:241\u20133.","journal-title":"Can Respir J"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0041-3879(86)90009-7","volume":"67","author":"PA Reeve","year":"1986","unstructured":"Reeve PA, Seaton D. Tuberculous empyema \u2013 a case history extending over 30\u00a0years. Tubercle. 1986;67:147\u201350.","journal-title":"Tubercle"},{"key":"1093_CR14","first-page":"748","volume":"70","author":"W McDermott","year":"1954","unstructured":"McDermott W, Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc. 1954;70:748\u201354.","journal-title":"Am Rev Tuberc"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1164\/ajrccm\/145.5.1223","volume":"145","author":"L Heifets","year":"1992","unstructured":"Heifets L, Lindholm-Levy P. Pyrazinamide sterilizing activity in vitro against semi-dormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis. 1992;145:1223\u20135.","journal-title":"Am Rev Respir Dis"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","volume":"66","author":"DA Mitchison","year":"1985","unstructured":"Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66:219\u201325.","journal-title":"Tubercle"},{"key":"1093_CR17","first-page":"13","volume-title":"Drug susceptibility in the chemotherapy of mycobacterial infections","author":"LB Heifets","year":"1991","unstructured":"Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, FL: CRC Press; 1991. p. 13\u201357."},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1378\/chest.88.5.792","volume":"88","author":"RE Neihart","year":"1985","unstructured":"Neihart RE, Hof DG. Successful nonsurgical treatment of tuberculous empyema in an irreducible pleural space. Chest. 1985;88:792\u20134.","journal-title":"Chest"},{"key":"1093_CR19","first-page":"30","volume":"107","author":"TM Johnson","year":"1973","unstructured":"Johnson TM, McCann W, Davey WN. Tuberculous bronchpleural fistula. Am Rev Respir Dis. 1973;107:30\u201341.","journal-title":"Am Rev Respir Dis"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1378\/chest.13-2250","volume":"146","author":"AR Haas","year":"2014","unstructured":"Haas AR, Sterman DH. Advances in pleural disease management including updated procedural coding. Chest. 2014;146:508\u201313.","journal-title":"Chest"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839\u201354.","journal-title":"Drugs"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1378\/chest.126.6.1722","volume":"126","author":"C Peloquin","year":"2004","unstructured":"Peloquin C. Use of therapeutic drug monitoring in tuberculosis patients. Chest. 2004;126:1722\u20134.","journal-title":"Chest"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-1093-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-1093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,11]],"date-time":"2016-10-11T17:08:04Z","timestamp":1476205684000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-1093-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,12]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-1093-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,12]]},"article-number":"327"}}